Luminex Corporation Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option

June 30, 2008 12:54 PM EDT

AUSTIN, Texas--(BUSINESS WIRE)--

Luminex Corporation (NASDAQ: LMNX) announced today the closing of its underwritten public offering of 4,025,000 shares of its common stock, including 525,000 shares issued in connection with the underwriters exercise of their over-allotment option following the pricing of the offering. The offering price to public was $19.91 per share.

The net proceeds from the offering were approximately $74.3 million, after deducting estimated expenses and underwriting discounts and commissions. Luminex intends to use the net proceeds from the offering for general corporate purposes, including research and development, potential acquisitions and capital expenditures.

J.P. Morgan Securities Inc. and UBS Investment Bank acted as joint book-running managers for the offering. Avondale Partners, LLC, Canaccord Adams Inc. and Leerink Swann LLC acted as co-managers for the offering.

An automatically effective shelf registration statement has been filed with the Securities and Exchange Commission which covers these securities. The offering was made solely by means of a prospectus and prospectus supplement. Copies of the prospectus and related prospectus supplement may be obtained by mail from: JPMorgan, National Statement Processing, Prospectus Library, 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245, telephone: 718-242-8002 or UBS Securities LLC, 299 Park Avenue, New York, NY 10171 Attn: Prospectus Department, or by telephone toll free at 888-827-7275, extension 3884. An electronic copy of the prospectus and related preliminary prospectus supplement are available on the website of the Securities and Exchange Commission at http://www.sec.gov.

About Luminex Corporation

Luminex develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry. The Company's xMAP(R) system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company's xMAP(R) technology is sold worldwide and is in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex or xMAP(R) can be obtained on the Internet at http://www.luminexcorp.com.

Statements contained in this press release that are not historical facts are "forward-looking" statements within the meaning of the federal securities laws. Forward-looking statements, including statements regarding the completion of the public offering and any of the terms thereof, are uncertain and subject to a variety of risks that could cause actual results to differ materially from those expected by the Company. Additional information regarding these and other risks effecting the Company are contained in the Company's registration statement and the prospectus supplement relating to the offering.

Source: Luminex Corporation

Related Categories

Press Releases

Stocks Mentioned

Related Entities

• UBS
• JPMorgan
• Canaccord Adams
• Avondale Partners

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?